Johnson & Johnson (JNJ) Stock Surges Past Record High as Wall Street Raises Price Targets

Key Highlights

• JNJ reached a record peak of $264.98 before climbing further to $268.69, posting a 3.70% daily gain
• Year-over-year total returns stand at an impressive 71%
• Guggenheim elevated its price objective to $270 with a Buy rating, projecting Q2 sales of $25.48 billion
• The company increased its quarterly payout to $1.34 per share from $1.30, extending its dividend growth streak to 55 years
• Major institutional players including Vanguard, State Street, and Norges Bank have significantly expanded their stakes

Johnson & Johnson shares reached unprecedented territory on Tuesday, initially touching $264.98 before advancing to $268.69 — representing a 3.70% intraday increase. This valuation positions the healthcare giant’s market capitalization at approximately $646.8 billion.

Johnson & Johnson, JNJ

Over the trailing twelve-month period, shares have climbed an impressive 71%, leaving the twelve-month trough of $154.21 far behind.

At present valuation levels, JNJ shows a price-to-earnings multiple of 31.02 and a PEG ratio of 2.58. The fifty-day moving average stands at $233.72, while the two-hundred-day average registers at $231.37 — both considerably beneath current trading levels.

Tuesday’s session saw volume of 1.79 million shares change hands, notably below the 8.41 million average. Such subdued volume accompanying price appreciation often signals methodical accumulation rather than speculative momentum.

Wall Street Targets Coming Into Play

Guggenheim recently elevated its price objective to $270 while reaffirming its Buy stance. The investment firm anticipates Q2 revenues reaching $25.48 billion with earnings per share of $2.87.

Leerink upgraded JNJ from Market Perform to Outperform in May, establishing a $265 price objective — a threshold the stock has now surpassed. Wells Fargo maintains an Overweight stance with a $263 target.

The aggregate view from 27 analysts points to a “Moderate Buy” recommendation, with an average price target of $257.13. The stock’s current trading level exceeds this consensus, indicating bullish momentum is outpacing Street expectations.

Bank of America and Barclays both maintain neutral/equal weight perspectives, with price objectives of $254 and $255 respectively.

Financial Performance and Shareholder Returns

The company’s latest quarterly results, disclosed April 14, revealed earnings per share of $2.70, exceeding the $2.68 consensus estimate. Revenues totaled $24.06 billion versus projections of $23.60 billion — marking a 9.9% year-over-year expansion.

The company also enhanced its quarterly distribution to $1.34 from $1.30, with the payment issued June 9. This translates to an annualized dividend of $5.36, yielding approximately 2.0% at current prices.

J&J has now delivered dividend increases for 55 straight years, maintaining its prestigious Dividend King status. The current payout ratio stands at 61.97%.

Fiscal 2026 EPS guidance spans $11.45–$11.65, with analyst consensus at $11.57.

Institutional Accumulation and Corporate Moves

Institutional ownership comprises 69.55% of outstanding shares. Vanguard expanded its position by 3.73 million shares in Q4, elevating its total to 240.35 million. State Street increased its holdings by 1.66 million to 133.87 million shares. Norges Bank initiated a new stake valued at approximately $6.92 billion.

Moran Wealth Management boosted its position by 15.4% during Q1, acquiring an additional 12,160 units to reach 90,903 shares, worth $22.2 million.

Regarding insider transactions, EVP Kathryn Wengel divested 10,000 shares at $241.15 on June 11, trimming her stake by 8.05%. She retains 114,288 shares valued at roughly $27.6 million.

The company also disclosed an investment exceeding $1 billion in its Jacksonville, Florida facilities to enhance manufacturing capacity for its Vision segment, including expanded production of ACUVUE contact lenses.

Fresh clinical data on IMAAVY (nipocalimab-aahu) for myasthenia gravis treatment was shared across 12 research abstracts at the European Academy of Neurology 2026 Congress.